Breakthrough Psychedelics

Three psychedelic substances including MDMA, psilocybin, and ketamine have been given breakthrough designations in clinical trial approval processes by the Food and Drug Administration (FDA). These three psychedelics represent three distinct 'classes' of psychedelics: phenethylamines (MDMA), tryptamines (psilocybin), and arylcyclohexylamines (ketamine). Ketamine has since been legally approved with MDMA and psilocybin projected for approval in the near future. This course aims to introduce persons to the clinical science, pharmacology, and use context of 'breakthrough psychedelics'.